Shire’s Adderall alternative granted EMA approval for EU

21/09/2015 - 2 minutes

Intuniv, Shire‘s new anti-stimulatory product for children with attention-deficit hyperactivity disorder (ADHD) between 6-17 years old, is set to hit shelves in Europe following successful market approval by the European medicine agency (EMA).

Shire_logoShire, a pharma giant with a €23.5Bn market cap, dominates the ADHD market. Originally from Basingstoke (England), they also have bases in the US (Cambridge, MA and Penssylvania). Now headquartered in DublinN (Ireland), in 2013 they announced their plans to reduce their UK presence to a minimum. Indeed, perhaps the most unusual movement by the company is their transfer of their taxable patents and revenue to Dublin (Ireland) where they can get by tax-free…making their ethos questionable.

Despite this, Shire’s latest development is making smiles all round: Intuniv (guanfacine hydrochloride) is a non-stimulatory  treatment for children who have shown intolerance to Adderall prescription. Adderall, as an amphetamine based psycho-stimulant, often has many side-effects that are particularly challenging in young children including insomnia, anxiety and weight-loss.

As an α2A adrenoceptor agnonist (of which there is a high concentration in the prefrontal cortex),

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member